Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579709 · ClinicalTrials.gov registry record · Phase 1
Thymus Transplantation With Immunosuppression
A Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00579709 is a Phase 1 study that has completed, run by Sumitomo Pharma Switzerland. The registered enrollment target is 15 participants.
The verdict
NCT00579709, a Phase 1 study, has completed, sponsored by Sumitomo Pharma Switzerland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The research purpose is to determine if thymus transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly. The research includes studies to evaluate whether thymus transplantation results in complete DiGeorge anomaly subjects developing a normal immune system.
Interventions
- BIOLOGICAL Thymus Tissue for Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-07 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579709
The ClinicalTrials.gov registry entry for NCT00579709 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thymus Tissue for Transplantation is the first listed.
NCT00579709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00579709 about?
NCT00579709 is a clinical study titled "Thymus Transplantation With Immunosuppression". The research purpose is to determine if thymus transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly. The research includes studies to evaluate whether thymus transplantation results in complete DiGeorge anomaly subjects developing a normal immune sys...
What is the current status of trial NCT00579709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2002-07. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00579709?
The interventions under investigation include: Thymus Tissue for Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00579709?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.